Expanded access to cheaper medicines for Australians living with type 2 diabetes 12 December 2024 Diabetes Australia thanks the Albanese Government for its decision to expand the Pharmaceutical Benefits Scheme (PBS) listings for Forxiga® and Xigduo®, making vital medicines more affordable and accessible for Australians living with type 2 diabetes. This initiative is set to benefit more than 100,000 people annually, reducing financial barriers and improving health outcomes. Type 2 diabetes affects more than 1.3 million Australians, with significant complications, costs, and daily impacts. Heart disease, the leading cause of death among people with diabetes, is closely linked to type 2 diabetes. The expanded PBS listing announced this week enables earlier access to these medicines for individuals at high risk of heart disease or those already living with it. Patients no longer need to wait for their blood glucose levels to rise to 7 percent before accessing these life-changing treatments. Forxiga and Xigduo reduce the risks associated with cardiovascular complications in diabetes. Without PBS subsidies, patients could face costs exceeding $600 annually for these treatments. Now, eligible individuals will pay a maximum of $31.60 per prescription or $7.70 with a concession card. This decision will contribute to timely access to medications that can help manage diabetes and prevent severe complications such as heart attacks, strokes, and organ damage. With Australia in the midst of a diabetes epidemic, removing barriers to treatment is a vital step toward easing the burden on individuals and the healthcare system.
Media releases 18 November 2026 Foundayo approval a welcome addition to GLP-1 treatment options Diabetes Australia has welcomed the TGA approval of Foundayo (orforglipron), a new oral GLP-1 receptor agonist for the management of type 2 diabetes and chronic weight management in eligible adults. Continue Reading
Media releases 6 November 2026 Diabetes Australia welcomes new oral GLP-1 treatment option for Australians Diabetes Australia welcomes the Therapeutic Goods Administration’s (TGA) recent approval of a new oral formulation of Wegovy (semaglutide) as a step forward in the treatment of obesity and related chronic conditions. Continue Reading
Media releases 15 October 2026 Resilience and strength of Nhulunbuy man recognised with Kellion Victory Medal Nhulunbuy man Gerald Buckle has been awarded a Kellion Victory Medal, marking 50 years of living with diabetes, at a ceremony alongside family and supporters in Darwin. Continue Reading